Statin-Antibiotic Combo Shows No Benefit for Decompensated Cirrhosis
(MedPage Today) -- Adding simvastatin and rifaximin to standard therapy for decompensated cirrhosis does not improve clinical outcomes, a double-blind phase III trial showed.
For the primary endpoint, no significant difference emerged for the...
For the primary endpoint, no significant difference emerged for the...